IQIYI Inc - ADR vs Eli Lilly And Co — how do they compare? IQIYI Inc - ADR trades at $1.35 (market cap $1.30B), while Eli Lilly And Co trades at $1,218.64 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 830.8× IQIYI Inc - ADR's market cap, and Eli Lilly And Co pays a 0.57% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals.
| IQ | LLY | |
|---|---|---|
Market Cap | $1.30B | $1.08T |
Sector | Media | Health |
52-Week High | $2.79 | $1.24K |
52-Week Low | $0.96 | $639.43 |
Enterprise Value | $2.88B | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
iQIYI (IQ) trades at $1.36, up 2.26% today, with a bullish technical signal from moving averages. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion. Valuation ratios show a high P/E of 144.05 but attractive P/S of 0.33 and P/B of 0.67. Recent news highlights AI platform growth and leadership changes, with Q2 2026 earnings due August 18, 2026.
The outlook is mixed: analyst consensus is 50% buy, but profitability challenges and revenue declines pose risks. Upside potential exists from AI initiatives and cost controls, yet competitive pressures and regulatory uncertainty in China remain headwinds. The stock offers speculative value for turnaround bets, balanced by fundamental weaknesses.
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →